Company profile
BEYONDSPRING INC.
NASDAQ:BYSIBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PLINABULIN | phase3 | — | 6 | completed, not_yet_recruiting, unknown |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02504489 | phase3 | completed | 2015-12-01 | 2021-07-21 | BeyondSpring Pharmaceuticals Inc. | Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC |
| NCT07361484 | phase3 | not_yet_recruiting | 2026-12-01 | 2029-06-01 | BeyondSpring Pharmaceuticals Inc. | Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) |
| NCT04227990 | phase2 | completed | 2017-11-27 | 2018-10-15 | BeyondSpring Pharmaceuticals Inc. | Plinabulin iv Solution in Prevention of TAC Induced Neutropenia |
| NCT04345900 | phase2 | completed | 2017-04-05 | 2018-03-20 | BeyondSpring Pharmaceuticals Inc. | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2 |
| NCT03102606 | phase3 | completed | 2018-05-29 | 2018-12-12 | BeyondSpring Pharmaceuticals Inc. | Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 |
FDA applications (0)
No records yet.